Morgan Stanley
CGON icon

Morgan Stanley’s CG Oncology CGON Stock Holding History

Morgan Stanley’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.6M Buy
1,177,109
+656,896
+126% +$42.9M ﹤0.01% 1727
2026
Q1 		$35.2M Sell
520,213
-24,806
-5% -$1.41M ﹤0.01% 2449
2025
Q4 		$22.6M Sell
545,019
-97,395
-15% -$4.03M ﹤0.01% 2821
2025
Q3 		$25.9M Sell
642,414
-1,225,734
-66% -$35.6M ﹤0.01% 2643
2025
Q2 		$48.6M Buy
1,868,148
+923,067
+98% +$22.2M ﹤0.01% 1961
2025
Q1 		$23.1M Buy
945,081
+219,854
+30% +$6.18M ﹤0.01% 2547
2024
Q4 		$20.8M Buy
725,227
+490,356
+209% +$16.8M ﹤0.01% 2714
2024
Q3 		$8.86M Buy
234,871
+140,162
+148% +$4.91M ﹤0.01% 3526
2024
Q2 		$2.99M Buy
94,709
+20,985
+28% +$727K ﹤0.01% 4294
2024
Q1 		$3.24M Buy
+73,724
New +$3.01M ﹤0.01% 4251

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's CGON Position: Q2 2026 in Review

Morgan Stanley increased its CG Oncology (CGON) stake by 126% in Q2 2026, buying an estimated $42.9M and bringing the position to 1,177,109 shares worth $83.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1727.

Morgan Stanley first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Morgan Stanley held 1,177,109 shares of CG Oncology worth $83.6M as of Q2 2026.
  • Morgan Stanley bought 656,896 CG Oncology shares in Q2 2026, an estimated $42.9M.
  • CG Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1727 holding.
  • Morgan Stanley first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.